Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated With Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1564-1572

  Klein, Samuel ^a   Mittendorfer, Bettina ^a   Eagon, J Christopher ^a   Patterson, Bruce ^a   Grant, LaFaine ^a   Feirt, Nikki ^b   Seki, Ekihiro ^b   Brenner, David ^b   Korenblat, Kevin ^a   McCrea, Jennifer ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FATTY ACID; GLUCOSE; INTERLEUKIN 8; LIPOPROTEIN; MACROPHAGE CHEMOTACTIC FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; EVALUATION; FEMALE; FIBROGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIVER DISEASE; LIVER FUNCTION; MALE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 33646339636     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.01.042     Document Type: Article

References (41)

1. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., and Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
3. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
4. Beymer C., Kowdley K.V., Larson A., Edmonson P., Dellinger E.P., and Flum D.R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 138 (2003) 1240-1244
5. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., Halavaara J., and Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 (2002) 3023-3028
6. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., and Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
7. Kelley D.E., Mokan M., Simoneau J.A., and Mandarino L.J. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 92 (1993) 91-98
8. Ferrannini E., Barrett E.J., Bevilacqua S., and DeFronzo R.A. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72 (1983) 1737-1747
9. Lewis G.F., Uffelman K.D., Szeto L.W., Weller B., and Steiner G. Interaction between free fatty acids and insulin in the acute control of very low-density lipoprotein production in humans. J Clin Invest 95 (1995) 158-166
10. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., and Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005) 603-608
11. Mittendorfer B., Patterson B.W., and Klein S. Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. Am J Physiol Endocrinol Metab 284 (2003) E549-E556
12. Palmer M., and Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99 (1990) 1408-1413
13. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., and Lefebvre P.J. Liver abnormalities in severely obese subjects. effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
14. Kral J.G., Thung S.N., Biron S., Hould F.S., Lebel S., Marceau S., Simard S., and Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 (2004) 48-58
15. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease. improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
16. Silverman E.M., Sapala J.A., and Appelman H.D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104 (1995) 23-31
17. Ranlov I., and Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 47 (1990) 208-214
18. Halverson J.D., Zuckerman G.R., Koehler R.E., Gentry K., Michael H.E., and DeSchryver-Kecskemeti K. Gastric bypass for morbid obesity. a medical-surgical assessment. Ann Surg 194 (1981) 152-160
19. Clark J.M., Alkhuraishi A.R., Solga S.F., Alli P., Diehl A.M., and Magnuson T.H. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13 (2005) 1180-1186
20. Capron J.P., Delamarre J., Dupas J.L., Braillon A., Degott C., and Quenum C. Fasting in obesity. another cause of liver injury with alcoholic hyaline?. Dig Dis Sci 27 (1982) 265-268
21. Andersen T., Gluud C., Franzmann M.B., and Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 (1991) 224-229
22. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis. summary of an AASLD Single Topic Conference. Hepatology 37 (2003) 1202-1219
23. Sugerman H.J., Starkey J.V., and Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 205 (1987) 613-624
24. Bataller R., Gabele E., Parsons C.J., Morris T., Yang L., Schoonhoven R., Brenner D.A., and Rippe R.A. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41 (2005) 1046-1055
25. Kweon Y.O., Goodman Z.D., Dienstag J.L., Schiff E.R., Brown N.A., Burchardt E., Schoonhoven R., Brenner D.A., and Fried M.W. Decreasing fibrogenesis. an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35 (2001) 749-755
26. Patterson B.W., Zhao G., Elias N., Hachey D.L., and Klein S. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res 40 (1999) 2118-2124
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment. insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
28. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82 (1959) 420-430
29. Mittendorfer B., Liem O., Patterson B.W., Miles J.M., and Klein S. What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean?. Diabetes 52 (2003) 1641-1648
30. Patterson B.W., Mittendorfer B., Elias N., Satyanarayana R., and Klein S. Use of stable isotopically labeled tracers to measure very low-density lipoprotein-triglyceride turnover. J Lipid Res 43 (2002) 223-233
31. Elias N., Patterson B.W., and Schonfeld G. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler Thromb Vasc Biol 20 (2000) 1309-1315
32. Horowitz J.F., Coppack S.W., and Klein S. Whole-body and adipose tissue glucose metabolism in response to short-term fasting in lean and obese women. Am J Clin Nutr 73 (2001) 517-522
33. Mittendorfer B., Horowitz J.F., and Klein S. Effect of gender on lipid kinetics during endurance exercise of moderate intensity in untrained subjects. Am J Physiol Endocrinol Metab 283 (2002) E58-E65
34. Boden G., and Shulman G.I. Free fatty acids in obesity and type 2 diabetes. defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 32 Suppl 3 (2002) 14-23
35. Horowitz J.F., and Klein S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am J Physiol Endocrinol Metab 278 (2000) E1144-E1152
36. Melish J., Le N.A., Ginsberg H., Steinberg D., and Brown W.V. Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am J Physiol 239 (1980) E354-E362
37. Mittelman S.D., and Bergman R.N. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279 (2000) E630-E637
38. Muscelli E., Mingrone G., Camastra S., Manco M., Pereira J.A., Pareja J.C., and Ferrannini E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 118 (2005) 51-57
39. Christiansen T., Richelsen B., and Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29 (2005) 146-150
40. Baggiolini M., Loetscher P., and Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 17 (1995) 103-108
41. Murphy F.R., Issa R., Zhou X., Ratnarajah S., Nagase H., Arthur M.J., Benyon C., and Iredale J.P. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. implications for reversibility of liver fibrosis. J Biol Chem 277 (2002) 11069-11076